Biomarkers
Increased Toll-like receptor 9 expression associated with cellular proliferation and poor prognosis in pleural mesothelioma
Journal of Pathology and Translational Medicine 2026 July [Link] Ali Omar Abdelaziz, Dina Moustafa Thabit, Rehab Mohamed Kamal, Hend Moness, Rasha Fouad Ahmed, Mariana Fathy Gayyed, Fatma El Zahraa Ammar Mohamed Abstract Background: Pleural mesothelioma is an aggressive malignancy with a poor prognosis. The epithelioid subtype is the most common and can be challenging to…
Read MoreFASN for diffuse malignant peritoneal mesothelioma: a prognostic biomarker after CRS+HIPEC and a therapeutic target
Journal of Translational Medicine 2026 May 21 [Link] Valentina Doldi, Chiara Maura Ciniselli, Claudia Aurelio, Enrica Favini, Silvio Marco Veronese, Fabio Bozzi, Shigeki Kusamura, Dario Baratti, Silvia Martini, Paolo Verderio, Marcello Deraco, Marco Folini, Paolo Gandellini, Sandro Pasquali, Nadia Zaffaroni Abstract Background: Diffuse malignant peritoneal mesothelioma (DMPM) is a rare and aggressive malignancy with limited…
Read MoreThe Diagnostic Value of Immunohistochemistry and Biomarkers in the Diagnosis of Mesothelioma in Pleural/Peritoneal Effusions
Diagnostic Cytopathology 2026 May 20 [Link] Suzanne M Selvaggi Abstract Background: Mesothelioma is a rare tumor that arises from the serosal cells lining the serous cavities, most commonly the pleura followed by the peritoneum. Presenting symptoms include pleuritic pain and bloody effusions that recur. Although cytologic analysis cannot determine the mesothelial subtype or in situ…
Read MoreClinical utility and prognostic value of GATA3 in epithelioid malignant mesothelioma: a practical and cost-effective approach for resource-limited settings
Journal of Clinical Pathology 2026 June 18 [Link] Dina Moustafa Thabit, Dalia M Thabet Abstract Aims: Distinguishing epithelioid malignant mesothelioma (EMM) from poorly differentiated lung adenocarcinoma (PD-LUAD) remains challenging, particularly when 21.7% of PD-LUADs lack lineage-specific markers (thyroid transcription factor-1 (TTF-1)/Napsin A), creating a diagnostic blind spot. While GATA-binding protein 3 (GATA3) is established in…
Read MoreDiagnostic Challenges in Pleural Mesothelioma
Cancers 2026 April 25 [Link] Moshe Lapidot, Martin Sattler Abstract Accurate diagnosis of PM and precise histologic subtyping are critical for optimal therapeutic decision-making, as treatment strategies-including chemotherapy, immunotherapy, or multimodality approaches-are largely subtype-dependent. Because of the several-decade latency between fiber inhalation and symptom onset, many cases are diagnosed at an advanced stage, when patients…
Read MorePrognostic Significance of Inflammatory, Cellular, and Tumor-Specific Biomarkers in Patients With Pleural and Peritoneal Mesothelioma
Clinical Lung Cancer 2026 June [Link] Keval Yerigeri, Manjistha Sengupta, Jingli Zhang, Jeevan Puthiamadathil, Raffit Hassan Abstract Background: Mesothelioma is an aggressive malignancy with poor outcomes, particularly when diagnosed at advanced stages. This study evaluated the prognostic value of tumor-specific biomarkers: soluble mesothelin-related peptide (SMRP), megakaryocyte potentiating factor (MPF) and CA125; inflammatory markers: C-reactive protein…
Read MoreImmunotherapy resistance and strategies in malignant pleural mesothelioma
Cancer Drug Resistance 2026 March 26 [Link] Wanyi Xia, Yulong Zhang, Juanzhi Zhao, Xiaoli Tan, Shaolong Ju, Wei Zou, Chaoqun Chen, Chunwei Li, Yanghua Xu, Yingming Peng, Shengqiao Li Abstract Malignant pleural mesothelioma (MPM) remains one of the most aggressive thoracic malignancies, characterized by profound resistance to conventional modalities such as surgery, chemotherapy, and radiotherapy,…
Read MoreTumor DNA methylation subtypes predict immunotherapy outcomes in pleural mesothelioma patients in the NIBIT-EPI-MESO study
Nature Genetics 2026 May [Link] Luana Calabrò, Francesca P Caruso, Alessia Covre, Teresa M R Noviello, Maria F Lofiego, Rossella Tufano, Luigi Ferraro, Piera Grisolia, Antonio De Falco, Vincenzo Lagano, Francesco Sgambelluri, Giovanna Sabella, Giulia Rossi, Giulia Gibilisco, Francesco Marzani, Emma Bello, Elena Simonetti, Vincenzo D’Alonzo, Michele Caraglia, Sandra Coral, Antonina De Angelis, Luigi Cerbone,…
Read MoreTumor DNA methylation subtypes predict immunotherapy outcomes in pleural mesothelioma patients in the NIBIT-EPI-MESO study
Nature Genetics 2026 May [Link] Luana Calabrò, Francesca P Caruso, Alessia Covre, Teresa M R Noviello, Maria F Lofiego, Rossella Tufano, Luigi Ferraro, Piera Grisolia, Antonio De Falco, Vincenzo Lagano, Francesco Sgambelluri, Giovanna Sabella, Giulia Rossi, Giulia Gibilisco, Francesco Marzani, Emma Bello, Elena Simonetti, Vincenzo D’Alonzo, Michele Caraglia, Sandra Coral, Antonina De Angelis, Luigi Cerbone,…
Read MoreEmerging Strategies in the Diagnosis and Treatment of Pleural Mesothelioma: An Overview
Thoracic Cancer 2026 April [Link] Raffaella Pagliaro, Beatrice Leonardi, Angela Schiattarella, Grazia Bergameo, Carmine Picone, Adolfo Gallipoli D’Errico, Filippo Scialò, Fabio Perrotta, Maria Luisa De Rimini, Alfonso Fiorelli, Andrea Bianco Abstract Pleural mesothelioma (PM) is a rare and aggressive cancer arising from pleural mesothelial cells with a strong association to asbestos exposure. Among the diagnostic…
Read More
Skip to content